Lauren D’Angelo (MBA ’07) | May 2021

D’Angelo (MBA 2007) was named Chief Commercial Officer of Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders. 

In this role, she will ensure the integrated commercial success of the company. Her initial focus will be to establish the company’s commercial strategy to effectively advance and position Alpha Cognition’s neurology pipeline, which includes leading all aspects of the U.S. commercial launch of the company’s lead program, ALPHA-1062, pending regulatory approval.

D’Angelo has more than 20 years’ experience leading successful drug commercialization efforts across 10 therapeutic areas including neurology. She most recently served as Vice President, Marketing and Commercial Strategy at Urovant Sciences, where she joined the company as employee #3, and led the commercial launch of GEMTESA®, the first new Overactive Bladder (OAB) drug treatment in more than 10 years. Prior to Urovant Sciences, D’Angelo held leadership roles in commercial development, marketing, operations and sales at Avanir Pharmaceuticals, Medivation, Genentech, and AstraZeneca. She has participated in more than 10 successful pharmaceutical drug launches, six of which have become blockbuster brands, including NEXIUM®, CRESTOR®, SYMBICORT®, SEROQUEL XR®, ONGLYZA® and XTANDI®.

Due to D’Angelo’s strong track record of success, she was recognized as Medical Marketing & Media’s 2017 Woman to Watch and was selected as one of Pharmaceutical Executive’s Emerging Pharma Leaders for 2020.